Palatin Technologies Inc. said on Wednesday that its sexual dysfunction drug candidate PT-141 induced a satisfactory erection in at least 80% of the subjects enrolled in a phase IIa trial of 24 patients who previously experienced an inadequate response to Pfizer Inc.’s sildenafil citrate (Viagra).
Given the results, Palatin President and CEO Dr. Carl Spana said the company would advance PT-141 to two phase IIb trials that will enroll 250 to 300 men with erectile dysfunction.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!